Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Parades Pipeline Before Investors During First US R&D Day

Executive Summary

Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.

You may also be interested in...



How Eisai Hopes To Expand In India

Japan's Eisai appears set for a significant step up in product introductions in India. Improving access to these medicines for patients in the largely self-pay market is at the fulcrum of its strategy, Dr Sanjit Singh Lamba, managing director of Eisai Pharmaceuticals India Pvt Ltd, tells Scrip. Newer options like a second brand approach may also be evaluated for certain new products to expand access and availability across the country.

Obesity Market Snapshot: Marketing Partners Giving Obesity The Slow Goodbye

After two years of almost nonexistent sales, analysts are ringing the death knell for the obesity market as revenues of once-promising obesity drugs continue to decline. The expectation is that virtually all of the major marketing partners will exit their respective partnerships in the near-term and more than one player could run out of cash.

AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes

AstraZeneca and Eli Lilly are to plough straight ahead with the Phase III part of the AMARANTH study testing their oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293 in early Alzheimer's after an encouraging interim safety review, building confidence in this potential disease-modifying drug class.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel